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BTHIRD ANNUAL INTERNATIONAL UMBILICAL CORD BLOOD
TRANSPLANTATION SYMPOSIUMLOS ANGELES, CALIFORNIA, JUNE 3-4, 2005ymposium Summary
John Wagner,1 Richard Champlin,2 Lawrence D. Petz3
1University of Minnesota, Minneapolis, Minnesota; 2M.D. Anderson Cancer Center, Houston, Texas; 3Stem Cyte
International Cord Blood Center, Arcadia, California
he 31-member faculty for the Symposium included leaders of the major transplant centers in the United States,
rance, Japan, Spain, and Taiwan. Attendees included visitors from Japan, New Zealand, Australia, Singapore,
rance, the United Kingdom, Israel, Mexico, Columbia, Cyprus, Switzerland, India, Sweden, Italy, Taiwan,
uwait, Saudi Arabia, the United Arab Emirates, Greece, Canada, Chile, Korea, and the United States.
he program was divided into 7 sessions: (I) umbilical cord blood transplantation (UCBT) in adults—current
esults and future directions; (II) infectious disease complications and immune reconstitution after UCBT;
III) approaches to augment the efﬁcacy of UCBT; (IV) collection, processing, banking, thawing, and adminis-
ration of umbilical cord blood (UCB) units—quality issues; (V) transplantation in children/genetic disorders;
VI) multipotent stem cells and regenerative medicine; and (VII) accreditation issues and the report from the
nstitute of Medicine. The following comments emphasize signiﬁcant aspects of selected presentations. Further
etails are provided in the abstracts that follow.
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mSession I reviewed UCBT in adults.
A large majority of patients in need of hematopoietic
ell transplantation are adults, and a signiﬁcant body of
ata is accumulating regarding the effectiveness of UCB
or this population. This is a most critical issue regarding
he ability of UCB units to fulﬁll society’s need for a
ource of stem cell products for all patients requiring a
ransplantation. The outcome results presented at the
ymposium were highly encouraging.
Dr. Eliane Gluckman presented a Eurocord analysis
he 3rd Annual International Umbilical Cord Blood Transplantation
ymposium was presented by the California Blood Bank Society and was
artially supported by unrestricted educational grants from StemCyte, the
ational Marrow Donor Program and the Health Resources Services
dministration (HRSA).
he 3rd Annual International Umbilical Cord Blood Bank Transplanta-
ion Symposium was partially ﬁnancially supported by a contract between
he Health Resources and Services Administration, U.S. Department and
ealth and Human Services, and the California Blood Bank Society. Any
pinions, ﬁndings, conclusions or recommendations expressed or presented
t this conference are those of the presenters and do not necessarily reﬂectrhe views of the U.S. Government.
B&MTf outcome results in 171 patients with hematologic
alignancies who underwent transplantation after
997. The median age of the patients was 29 years
range, 15-55 years), and the median follow-up time
as 18 months (range, 1-71 months). At 2 years,
isease-free survival for patients who underwent
ransplantation in the early, intermediate, and ad-
anced phase of disease was 41%  9%, 34%  10%,
nd 18%  4%, respectively. Also, a matched-pair
nalysis was performed to compare the results of
LA-mismatched UCB and HLA-matched bone
arrow transplantations (BMT) from unrelated do-
ors in adults with acute leukemia. The 2-year cumu-
ative incidences of chronic graft-versus-host disease
GVHD), transplant-related mortality (TRM), leuke-
ia relapse, 2-year probability of survival, and leuke-
ia-free survival were not signiﬁcantly different.
A comparison was also performed with hap-
oidentical related peripheral blood transplants.
here were 220 patients with acute myeloid leuke-
ia (AML) and 148 with acute lymphocytic leuke-
ia (ALL), and these groups were analyzed sepa-ately. In those with AML, TRM (58% versus 46%)
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9nd the rate of relapse (24% versus 18%) were not
ifferent. In contrast, in those with ALL, the leu-
emia-free survival was higher in patients who re-
eived with UCB compared with haploidentical
MT (36% versus 13%). The difference was more
igniﬁcant in patients who underwent transplanta-
ion in second complete remission or more ad-
anced disease.
These data suggest that, despite increased HLA
isparity, UCB from unrelated donors offers results
omparable to those with HLA-matched unrelated
MT in adults with acute leukemia. Therefore, the
onor search process for bone marrow (BM) and UCB
rom unrelated donors should be started simulta-
eously in adults, especially in patients with acute
eukemia, for whom time is very important. The
hoice of units containing a higher nucleated cell
NC) dose and a policy of earlier transplantation are
ikely to provide better results.
Dr. Pablo Rubinstein reported on the results of
750 UCBTs performed since 1993 with units pro-
ided by the New York Blood Center. Of these, 396
ecipients (22.6%) were 16 years old. Of the adults,
5% were 25 years old, 90% had hematologic ma-
ignancies, 33% had advanced disease (International
one Marrow Transplantation Registry classiﬁcation),
3% had received a prior autograft or allograft, and
1% received double-unit transplants. Engraftment
as associated with the total nucleated cell (TNC)
ose (P  .004) and HLA matching (P  .003), espe-
ially when recipients of transplants mismatched only
n the graft-versus-host direction were counted as
atched (P  .001). Signiﬁcant differences in the
robability of engraftment were also related to the
onditioning regimens and to the use of double-unit
ransplantation. Within the adult group, age at trans-
lantation was not signiﬁcantly related to the proba-
ility of survival at 1 or 5 years. The difference in
-year survival between recipients of grafts with 2.5
r 2.5  107 NCs per kilogram was not signiﬁcant.
he absence of HLA rejection mismatches was signif-
cantly associated with survival at 1 year (68% versus
7%; P  .005). Overall survival was 23% at 5 years.
ngraftment and survival were signiﬁcantly better in a
roup of 45 patients given a 2-unit transplant, most of
hom also were treated with a ﬂudarabine-containing
egimen.
Dr. Satoshi Takahashi reported on results compar-
ng UCBT and BMT at Tokyo University. Results
ndicate that UCBT from unrelated donors has efﬁ-
acy comparable to that with BMT from unrelated
onors and can restore hematopoiesis with acceptable
oxicities in adults. He reported the clinical outcomes
f 92 adult patients with hematologic malignancies
58% high risk) who received UCBT from unrelated
onors after myeloablative conditioning. The median
ollow-up was 22 months (range, 1-82 months). The h
22-year probability of TRM was 20%, and the 2-year
robability of relapse was 18%. The 2-year probabil-
ties of disease-free survival were 95% in standard-risk
atients (n  39) and 60% in high-risk adult patients
n  53).
Dr. John Wagner reported on UCBT after non-
yeloablative therapy in 51 high-risk adults and ado-
escents with advanced hematologic malignancies. Ap-
roximately 1 in 4 (approximately 13 patients)
eceived single and 3 in 4 (approximately 38 patients)
eceived double UCB grafts. Units were predomi-
antly 1- and 2-HLA antigen–mismatched with the
ecipient. Stratiﬁed into those with and without che-
otherapy in the prior 4 months, the cumulative in-
idences of sustained donor engraftment were 98%
nd 64% (P  .03), respectively. The incidence of
latelet recovery (50 000/L) was 68%. The inci-
ences of grade II to IV and grade III/IV acute
VHD were 63% and 25% at day 100, and the
ncidence of chronic GVHD was 28% at 1 year. TRM
as 19% at day 180. Regression of relapsed or persis-
ent disease has been seen in patients with myelodys-
lasia and intermediate- and low-grade lymphoid ma-
ignancies. The probability of overall survival at 1 year
s 44%. Notably, only ﬁtness, and not age, was asso-
iated with poor outcome. The data indicate that the
egimen is well tolerated and sufﬁcient for engraft-
ent, particularly in patients with chemotherapy in
he preceding 4 months. This approach extends access
o transplantation to many adults who would other-
ise be ineligible because of the lack of a donor or the
nability to tolerate high-dose conditioning.
Dr. Haruko Tashiro presented data comparing the
utcome in adult UCBTs between myeloablative and
onmyeloablative conditioning regimens. The my-
loablative group consisted of 30 patients (median age,
3 years) with AML, ALL, non-Hodgkin lymphoma
NHL), myelodysplastic syndrome, and chronic my-
logenous leukemia (CML). The nonmyeloablative
roup consisted of 22 patients (median age, 55 years)
ith AML, ALL, myelodysplastic syndrome, chronic
yelomonocytic leukemia, NHL, Hodgkin disease,
nd chronic lymphocytic leukemia (CLL). The results
ndicated that the rate of engraftment failure, includ-
ng conditioning failure and autologous recovery, was
7% in the myeloablative group and 32% in the non-
yeloablative group. Neutrophils were engrafted at
ay 23 and day 21 (median) in the myeloablative and
onmyeloablative groups, respectively. The cumula-
ive incidence of grade III/IV acute GVHD was 26%
n the myeloablative group and 40% in the nonmy-
loablative group. The conclusion was that there were
o signiﬁcant differences in the probability of engraft-
ent or in the duration to the engraftment of neutro-
hils between the 2 groups. The incidence of grade
II/IV GVHD in the nonmyeloablative group was
igher than that in the myeloablative group.
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BDr. Juliet Barker presented results of UCBT of 16
dult patients (aged 37-67 years) with advanced or
efractory follicular NHL (n  7), CLL (n  6), or
antle cell lymphoma (n  3). A nonmyeloablative
onditioning regimen was used. Thirteen had sus-
ained donor engraftment. Grade II to IV acute and
xtensive chronic GVHD was seen in 12 and 6 pa-
ients, respectively. Four patients (3 with follicular
HL and 1 with CLL) have died with progressive
isease, and 12 are alive in complete remission be-
ween 180 and 1214 days after transplantation. Two of
he 3 patients with failure of donor engraftment were
alvaged with a single cycle of cyclophosphamide, vin-
ristine, and prednisone. The lack of intensive com-
ination chemotherapy immediately before transplan-
ation may have contributed to their risk for graft
ejection. The conclusion reached was that these pre-
iminary results in indolent NHL, including CLL and
antle cell lymphoma, are encouraging, with 12 of 16
atients in sustained complete remission. Prior ther-
py is likely an important factor in donor engraftment,
nd the incidence of severe GVHD has been low.
atient referral before the development of refractory
isease should be considered.
Dr. John Wagner presented results of double
CBT in the setting of a myeloablative preparative
herapy. Because recipients of 2.5  107 NCs per
ilogram have slow hematopoietic recovery and a sig-
iﬁcantly lower incidence of engraftment, 2 partially
LA-matched units were used to augment the cell
ose. Thirty-one adult and adolescent patients with
igh-risk hematologic malignancies underwent trans-
lantation with 2 partially HLA-matched UCB units
fter myeloablative conditioning. Patients had AML
n  15), ALL (n  12), CML (n  3), or NHL (n 
). The median total infused dose was 3.7  107 NCs
er kilogram (range, 1.1-6.3) and 4.9  105 CD34
ells per kilogram (range, 0.9-14.5). All patients en-
rafted at a median of 23 days (range, 14-41 days),
ith 1 unit predominating. No factor predicted which
nit would predominate. The incidence of platelet
ecovery (50 000/L) was 73% at day 180. The
ncidence of grade II to IV and III/IV acute GVHD
as 65% and 17%, respectively, at day 100. Disease-
ree survival was 72% at 1 year for patients who
nderwent transplantation in complete remission,
ith no relapse in this cohort (median follow-up, 1.2
ears). These data suggest that (1) double-unit UCBT
s safe, with 1 unit predominating over time; (2) dou-
le-unit UCBT extends the application to nearly all
dults and adolescents; and (3) survival exceeds histor-
cal data with a single UCB unit.
Dr. Manuel N. Fernandez reported the results of a
ovel approach to augment engraftment after unre-
ated single UCBT. The approach is the coinfusion of
he best available UCB unit (3/6 HLA mismatch and
NCs 1.5  107/kg) and a limited number (2-2.5  k
B&MT06/kg) of highly T cell–depleted (CD3 10 000/
g) mobilized peripheral blood stem cells after a my-
loablative conditioning regimen. Twenty-eight high-
isk adult patients (median age, 30 years; range, 16-60
ears) underwent consecutive transplantations. The
edian TNC of the transplanted UCB units was 2.37
107/kg (range, 1.31-3.70), and the median CD34
ell count was 0.11  106/kg (range, 0.035-0.37). The
hird-party donor cells infused consisted of CD34
2.31  106/kg; range, 1.05-2.58) and CD3 (2.5 
03/kg; range, 0.50-9.80). After a median follow-up of
0 months (range, 1-75 months) for all patients and 16
onths (range, 3-75 months) for the 20 living patients
9 survived 2 years), the 4-year overall survival is
7% for the entire group and 86% for the 19 after
xclusion of the 5 older than 40 years and the 4 with
aternal haploidentical peripheral blood stem cells.
his strategy makes UCBT feasible as a ﬁrst choice
or most patients of a wide age range and may allow
dditional immunotherapeutic maneuvers.
Session II reviewed infectious disease compli-
ations and immune reconstitution after UCBT.
Dr. Jo-Anne van Burik reviewed infectious com-
lications after unrelated UCBT. The reports of sev-
ral large series of patients were reviewed, as was
he epidemiology of individual infections, including
acteria, tuberculosis, pertussis, herpes simplex virus,
aricella-zoster virus, cytomegalovirus, and human
erpesvirus (HHV)–6 infections. Of 362 UCB sam-
les tested by polymerase chain reaction, none had
ytomegalovirus, Epstein-Barr virus, HHV-7, or
HV-8, and 2 had HHV-6. Among patients who die,
ost studies indicate a 30% to 40% rate of infection.
acterial infections often occur before engraftment
nd may lead to graft failure. Delayed recovery of the
mmune response among patients with GVHD leads
o viral infections, including at later time points. The
isk of serious infection in UCBT is comparable to
hat with unmanipulated marrow transplantation.
Dr. Mary Laughlin reviewed the incidence of and
isk factors for early severe infections after UCB.
ontributing factors to bacterial, viral, and fungal
nfections occurring during the ﬁrst 100 days after
nrelated UCBT share features common to those
bserved after allogeneic transplantation with conven-
ional marrow or peripheral blood stem cell grafts
rom adult donors. These contributing factors include
ost variables (age and underlying disease), type of
onditioning (ablative or reduced intensity), duration
f neutropenia, acute GVHD incidence and severity,
nd receipt of corticosteroids. In addition, preliminary
linical data point to possible unique UCB graft fea-
ures that contribute to infections at these early time
oints, including UCB stem cell and accessory cell
opulations. The graft cell dose may also affect the
inetics of myeloid and lymphocyte reconstitution.
923
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9Dr. Nelson Chao discussed immune reconstitution
fter UCBT and pointed out that recovery of immu-
ity involves reconstitution of the innate and adaptive
mmune cells and their respective function. T-cell
econstitution early after UCBT involves expansion of
CB T cells that are infused with the stem cells. This
rst wave of T cells is a result of peripheral expansion
n secondary lymphoid organs. After peripheral ex-
ansion, there is a slower second wave of donor-
erived precursors that come from the engrafted do-
or cells. These cells trafﬁc through the thymus and
re educated there. T-cell receptor excision circles
single joint [sj] TRECs) are generated within the
hymus and identify new thymic emigrants and those
hat have not divided. Measurements of TRECs, spec-
ratyping of the T-cell receptor V families, and ex-
ensive phenotypic analyses have allowed determina-
ion of the time course of T-cell reconstitution and of
ome of the factors that contribute to or detract from
apid recovery. T-cell recovery after UCBT occurs
rimarily through peripheral expansion of adoptively
ransferred donor T cells and results in skewing of the
-cell repertoire. The reappearance of sjTREC-con-
aining cells after UCBT is associated with increasing
umbers of phenotypically naive T cells, improved
itogen and recall antigen responses, and diversiﬁca-
ion of the T-cell repertoire. The delay in central
-cell recovery in adults relative to children may be
ue to differences in thymic function resulting from
ge-related atrophy, GVHD, or the pharmacologic
ffects of prophylaxis and treatment of GVHD.
Session III reviewed approaches to augment
he efficacy of UCBT.
Dr. Bruce Blazar discussed the physiology of reg-
latory T cells and their role as a treatment modality.
egulatory T cells are a subpopulation of naive CD4
cells that coexpresses CD25, the interleukin 2 re-
eptor 	 chain, and exhibits potent suppressor activity.
D4CD25 cells play a vital role in the induction
nd maintenance of peripheral self-tolerance and the
revention of systemic autoimmune disorders, includ-
ng autoimmune gastritis, intestinal inﬂammation, and
utoimmune diabetes in diabetes-prone (nonobese di-
betic) mice. CD4CD25 cells regulate T-cell al-
oresponses and tolerance induction. Depletion of
D4CD25 cells augments a mixed lymphocyte re-
ction culture, whereas adding a graded number of
D4CD25 T cells results in a dose-response re-
uction in alloproliferation. Supplementation of the
onor graft with donor but not host CD4CD25
ells had a marked amelioration of GVHD lethality in
ultiple strain combinations. Because CD4CD25
ells are capable of suppressing both CD4 and
D8 T cells, it is reasonable to assume that
D4CD25 cells may be beneﬁcial in suppressing
ost antidonor responses that can cause BM graft s
24ejection. This has now been demonstrated by 3 sep-
rate groups by using distinct model systems. Recent
tudies have shown that UCB CD4CD25 cells are
ore readily isolated and more often lead to high
evels of suppression as compared with adult periph-
ral blood mononuclear cells. These preliminary ﬁnd-
ngs demonstrating a high degree of mixed lympho-
yte reaction suppression now have been extended in
ubsequent studies, with 100 UCB lines generated
o date. Thus, the stage is set for clinical trials of
D4CD25 cells for GVHD inhibition and therapy
nd for engraftment promotion.
Dr. Elizabeth Shpall discussed transplantation of ex
ivo–expanded UCB. She reported a study of 43 pa-
ients in whom ex vivo expansion of UCB was done in
n attempt to improve time to engraftment and reduce
he graft failure rate in the recipients. A fraction of
ach patient’s UCB allograft was CD34-selected and
ultured ex vivo for 10 or 14 days before transplanta-
ion in deﬁned media with stem cell factor, granulo-
yte colony-stimulating factor, and megakaryocyte
rowth and differentiation factor. The remainder of
he UCB graft was infused without further manipula-
ion. This study demonstrated that CD34 selection
nd ex vivo expansion of UCB before transplantation
s feasible. The engraftment failure rate was relatively
ow, and the time to neutrophil engraftment in large
dults was in the range reported for pediatric recipi-
nts of much larger UCB cell doses. In a subsequent
xpansion trial, patients are now being randomized to
eceive either 2 unmanipulated UCB units or 1 un-
anipulated unit plus 1 unit from which all the cells
re expanded ex vivo. Another expansion trial technol-
gy involves the use of a copper chelating agent that
as been shown to enhance the expansion of a more
rimitive CD34 UCB population when combined
ith early-acting growth factors.
Dr. Mary Laughlin reported transplantation out-
omes for 2 adults with CML who received myeloa-
lative conditioning followed by infusion of a non-
xpanded single UCB graft containing a low
ononuclear cell dose. These patients were enrolled
n a supportive care clinical transplantation trial in-
orporating in vivo administration of recombinant hu-
an stem cell factor (R-MetHuSCF) and ﬁlgrastim
dministered concomitantly from the day of UCB
nfusion to the time of donor-derived hematopoietic
ecovery. Each patient engrafted promptly. The time
o a donor-derived absolute neutrophil count
500/L was 13 and 29 days. No adverse events
ttributable to R-MetHuSCF injections were ob-
erved. In vivo UCB expansion with administration of
oncomitant R-MetHuSCF and ﬁlgrastim may be an
lternate strategy to facilitate prompt donor hemato-
ogic engraftment in adult UCBT recipients.
Dr. Juliet Barker presented the standard practice of
electing units that are HLA 4/6 to 6/6 matched with
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Bhe patient with cell doses that exceed 2.5  107 NCs
er kilogram of recipient body weight. However, ad-
itional analysis of the outcome of US patients who
nderwent transplantation with a single-unit myelo-
blative conditioning demonstrated that a cell dose of
2.5  107 NCs per kilogram is required for recipi-
nts of 5/6-matched units to achieve at least 50%
urvival at 1 year, whereas in 4/6 recipients the cell
ose needs to exceed 5  107 NCs per kilogram to
chieve a similar outcome. One possible strategy to
mprove adult UCBT outcomes is to use double unit
rafts. This strategy for selection of 2 units thus far
as included the requirement that all units contain at
east 2.0  107 NCs per kilogram, and of those, the
ore closely matched units would be infused. The
nits must be no more than 2-antigen mismatched
ith the recipient and with each other, according to
he current Minnesota protocol. Currently, it is rea-
onable for all patients to undergo a volunteer adult
onor search and a UCB search at the time of referral.
onor choice will depend on patient diagnosis, the
rgency of transplantation, the relative availability of
n adequately matched volunteer donor versus a UCB
nit of adequate dose and match, physician prefer-
nce, and research priorities. A volunteer donor may
e preferred for a patient with CML in chronic phase
r early accelerated phase and possibly other diag-
oses, such as myeloﬁbrosis or severe aplastic anemia.
f the transplantation is urgent, UCB is a clear advan-
age, although a volunteer donor could possibly be
btained by using a National Marrow Donor Program
NMDP) ultra urgent search strategy.
Dr. Hal Broxmeyer discussed strategies to improve
oming of UCB stem cells as another approach to
nhance engraftment in recipients of UCB. Not all
ouse hematopoietic stem cells (HSCs) home with
bsolute efﬁciency. The chemokine stromal cell–de-
ived factor–1 (SDF–1/CXCL12 and its G	 protein–
inked 7 transmembrane–spanning receptor CXCR4
re involved in chemotaxis, mobilization, and homing
f HSCs. CD26 is a cell-surface dipeptidylpeptidase
V that can truncate SDF-1/CXCL12. Inhibition or
eletion of CD26 in target populations containing or
ighly enriched for human UCB and human and mu-
ine BM HSCs and hematopoietic progenitor/stem
ells (HPCs) greatly enhanced the chemotactic re-
ponsiveness of these cells to SDF-1/CXCL12. Inhi-
ition or deletion of CD26 in mice was associated
ith a greatly decreased ability to mobilize HPCs with
ranulocyte colony-stimulating factor. Recent work
as found that in vitro inhibition of CD26 on human
D34 UCB cells enhances the engraftment of these
ells in sublethally irradiated nonobese diabetic/severe
ombined immunodeﬁciency mice. These encourag-
ng results with UCB cells suggest that targeting
D26 or other means of enhancing homing/engraft-
ent may be of practical value in a clinical setting to p
B&MTse limiting numbers of UCB HSCs for successful
ransplantation.
Session IV reviewed collection, processing,
anking, thawing, and administration of UCB
nits—quality issues.
Dr. Joanne Kurtzberg discussed the standardization
f UCB banking procedures in the NMDP network,
hich functions as a program within the NMDP that
ses common standards for UCB donors, collection,
rocessing, and storage listing on a single registry in
ombination with volunteer adult donors.
Dr. Jeffrey McCullough discussed quality issues in
CB banking. Of 268 units of UCB shipped for
ransplantation to the University of Minnesota during
3-year period, 151 (56%) had 1 or more issues
otentially related to quality that required evaluation
efore a ﬁnal decision regarding their suitability for
se. There were 246 speciﬁc issues in 151 units. The
ssues involved quality control (54%), medical history
40%), and labels and documentation (6%). Risks to
atients from these issues were judged to be likely in
0%, potential in 35%, and unlikely in 55%.
Dr. Rafael Bornstein presented data comparing pre-
ryopreservation and postcryopreservation CD34
ounts from UCB units. An evaluation was performed
t the Madrid Cord Blood Bank (MCBB) and at the
niversity of Minnesota (UM) of 50 duplicate cryo-
reserved UCB aliquots (1.5-mL cryovials) from UCB
nits stored according to standard banking proce-
ures. After shipment with a transport liquid nitrogen
ontainer, the aliquots were thawed and processed by
he same protocol at both the UM and MCBB. Results
ere discrepant, but linear regression showed a sig-
iﬁcant relationship (P  .001), and it was possible to
oresee with a conﬁdence of 95% the thawed CD34
ell dose that would be infused to UCBT patients at
he UM either from the prefreeze MCBB data or from
he CD34 assessment with a cryopreserved aliquot.
hereas this regression model is speciﬁc for the UM
nd MCBB, the principle is that this approach could
e widely applied to predict the transplantation out-
omes from CD34 data provided by all UCB banks.
Dr. Emer Clarke discussed standardization of col-
ny-forming cell assays. Previously published data
ave indicated signiﬁcant variability in the quantiﬁca-
ion of hematopoietic progenitors by using the colo-
y-forming cell assay. Two distinct proﬁciency-test-
ng programs were designed to assess the contribution
f various parameters to the variability. There were 54
articipants in the ﬁrst program and 134 in the sec-
nd. The considerable increase in the coefﬁcients of
ariation in the second test conﬁrmed that sample-
reparation steps contribute signiﬁcantly to the vari-
bility in this assay. Standardized protocols for cell
reparation and training will decrease this variability
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9nd facilitate the global applicability of data generated
rom various laboratories.
Dr. Michael Creer discussed postthaw characteriza-
ion of progenitor cell viability in UCB products. The
igniﬁcance of variations in the process of cryopreser-
ation was evaluated, as was the signiﬁcance of cell
ashing. The evaluation of cell washing indicated that
ell washing to remove dimethyl sulfoxide, red blood
ell stroma, and plasma after thawing is not necessary
hen UCB products are red blood cell–depleted and
lasma-depleted before cryopreservation. At present,
he only way to assess postthaw HPC functional via-
ility is to measure colony-forming activity. Addi-
ional research needs to be performed to improve the
tandardization of measurements of colony-forming
ell content and to identify potential alternative ap-
roaches to assess HPC functional viability with
reater precision and correlation with transplantation
utcome.
Session V reviewed transplantation of chil-
ren/genetic disorders.
Dr. Joanne Kurtzberg discussed unrelated UCBT
n pediatric patients with nonmalignant diseases, fo-
using on outcomes in 69 patients with inborn errors
f metabolism who underwent transplantation be-
ween August 1999 and June 2004. The patients were
iagnosed with mucopolysaccharidoses syndromes
57%), adrenoleukodystrophy (12%), metachromatic
eukodystrophy (6%), Krabbe disease (23%), and Tay-
achs disease. The cumulative incidence of overall
urvival was 80% (95% conﬁdence interval, 71%-
0%) and 72% (95% conﬁdence interval, 61%-83%)
t 180 and 365 days, respectively. Improved growth
nd cognitive function were seen in patients with
urler syndrome and neonates with Krabbe disease.
Dr. Eliane Gluckman reported the results of several
tudies of UCBT in children. One study concerned 95
hildren who underwent UCBT for AML, and a sec-
nd study concerned 195 patients who underwent
ransplantation for ALL. A third study concerned a
ulticenter retrospective analysis comparing the out-
ome of unrelated UCBTs (n  99) with that of
nrelated BMT (unmanipulated or T-cell depleted; n
416) in children with acute leukemia. The results
ustify the simultaneous search for unrelated UCB and
nrelated BM donors for children with acute leuke-
ia. The decision to perform unrelated UCBTs will
e based on the cell content of the graft, the number
f HLA disparities, and the urgency of the transplan-
ation.
Dr. Tang-Her Jaing reported on the outcome of
nrelated UCBT in 9 young children with -thalas-
emia major. Eight of the 9 patients are alive at me-
ian follow-up of 254 days after transplantation, with
omplete donor chimerism and transfusion indepen-
ence. These results suggest that unrelated UCBT is w
26n alternative treatment for young patients with trans-
usion-dependent thalassemia who lack an HLA-
atched sibling donor. The high degree of success
ay relate to the fact that patients underwent trans-
lantation at a young age, before complications of the
isease developed (Lucarelli class I), and to the use of
igh cell doses.
Dr. David Jacobsohn discussed the outcomes of
nrelated UCBTs (4/6-5/6 HLA matched) and allo-
eneic related hematopoietic BM or peripheral blood
tem cell transplantations (6/6 HLA matched) in chil-
ren with high-risk ALL. There were 23 matched
ibling (20 BM and 3 peripheral blood stem cell) and
6 UCB recipients. TRM and GVHD were equal in
oth groups. The 3-year event-free survival was 60%
n both groups. Age, sex, degree of HLA matching for
CB, and acute or chronic GVHD did not affect
vent-free survival. Thus, in pediatric patients with
igh-risk ALL in need of HSC transplantation, the
utcome of matched-sibling HSC transplantation and
CBT is equivalent with regard to TRM, GVHD,
nd event-free survival. UCB should be considered a
tandard stem cell source to use in this group when a
atched sibling is not available.
Dr. Demetrios Petropoulos presented favorable re-
ults in pediatric patients with advanced hematologic
alignancies by using a reduced-intensity regimen of
udarabine 30 mg/m2 intravenously for 4 days, mel-
halan 140 mg/m2 intravenously for 1 day, and 9 Gy
f total body irradiation in 3 single daily fractions of 3
y. GVHD prophylaxis consisted of tacrolimus and
inimethotrexate.
Session VI reviewed multipotent stem cells
nd regenerative medicine.
Dr. Catherine Verfaillie discussed a population of
rimitive cells in normal human, rodent, and swine
ostnatal tissues that have, at the single-cell level,
ultipotent differentiation and extensive proliferation
otential. These cells have been named multipotent
dult progenitor cells. Improved isolation processes
ave now generated cells with Oct4 levels that vastly
xceed the levels in multipotent adult progenitor cells
reviously published. This improvement has led to
igniﬁcantly greater differentiation ability and signif-
cantly greater in vivo engraftment ability.
Dr. Darwin Prockop discussed mesenchymal stem
ells. Preparations of mesenchymal stem cells vary in
uality from laboratory to laboratory; there is little, if
ny, standardization, and different results are obtained
ith cells called by the same names. A National Insti-
utes of Health–sponsored effort is under way to de-
elop and distribute standardized preparations of mes-
nchymal stem cells from marrow.
Dr. Curtis Cetrulo presented results on Wharton
elly as a source of multipotent mesenchymal cells
ith high telomerase activity that have the capability
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Bo differentiate into bone, cartilage, muscle cells (car-
iac), and nerve cells. The goal is to develop these
ells as accessory supporting cells for UCBT.
Dr. Esmail Zanjani discussed the in vivo poten-
ial of human HSCs in a random-bred noninjury
arge-animal model in sheep. The plasticity poten-
ial of marrow, peripheral blood stem cells, and
CB stem cells was studied in vivo. Naturally oc-
urring biological events in the early preimmune
etus include (1) developing sites for HSC engraft-
ent, (2) large-scale HSC migration, (3) assimila-
ion of donor HSCs, (4) a permissive tissue-speciﬁc
nvironment, (5) high-level cellular proliferation in
eveloping tissues and organs, and (6) immune na-
veté. These events result in a reduced ability to
eject human HSCs, permit the induction of donor-
peciﬁc tolerance, and allow the long-term persis-
ence of donor cells. These characteristics permit
he detection of the full in vivo potential of human
SCs. Possible uses of the model include the study
f in vivo activity of human HSCs, generation of
onor-speciﬁc human cells, generation of donor-
peciﬁc “humanized” organs, and generation of ge-
eric human cells or organs.
Session VII reviewed accreditation issues and
he report from the Institute of Medicine.
Dr. Phyllis Warkentin discussed the NETCORD/
oundation for the Accreditation of Cellular Ther-
py (FACT) international UCB banking standards.
he reviewed the history of FACT/NETCORD,
he goals of the program, the standard-setting pro-
ess, the scope of the standards, the accreditation w
B&MTrogram, and the inspections process and potential
utcomes.
Dr. James McMannis reviewed the AABB stan-
ards and accreditation for UCB. For almost 60
ears, the AABB has applied its extensive experience
n standard setting, education, and accreditation
rograms to related biological therapies, including
CB collection and processing. Standards integrate
uality-management systems with technical re-
uirements and apply to donor selection, eligibility,
roduct processing, storage, and issuance, including
utcomes data collection. The AABB works closely
ith other organizations, eg, the Food and Drug
dministration, International Society for Cellular
herapy, NMDP, FACT, and American Society for
lood and Marrow Transplantation, sponsoring
oint educational programs and serving on joint
ommittees. AABB believes that each organization
rings speciﬁc experience and expertise to a national
CB program.
Dr. Richard Champlin reviewed the Institute of
edicine report on UCBT. In 2004, the US Con-
ress appropriated $10 million for the establish-
ent of a National Stem Cell Bank Program under
he Health Resources and Services Administration.
he Institute of Medicine was commissioned to
eview the use of UCB for stem cell treatment and
ake recommendations regarding a national system
o support UCBT. The recommendations of the
ommittee are included in a detailed report that is
vailable to the public on the Internet at http://
ww.nap.edu/books/0309095867/html.
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